查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854533

MRI造影剂市场按产品类型、药物类别、应用、最终用途、分销管道和给药途径划分－2025-2032年全球预测

MRI Contrast Media Agents Market by Product Type, Agent Class, Application, End Use, Distribution Channel, Administration Route - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，MRI造影剂市场规模将达到 48.9 亿美元，复合年增长率为 7.83%。

主要市场统计数据
基准年 2024 26.7亿美元
预计年份：2025年 28.8亿美元
预测年份：2032年 48.9亿美元
复合年增长率 (%) 7.83%

本书权威地介绍了磁振造影造影剂，阐述了其化学多样性、临床效用以及安全性造影产品开发和临床应用的重要性。

磁振造影造影剂是现代影像的关键，它们能够增强组织对比度，并使各种临床适应症的影像解读更加可靠。钆基对比剂长期以来在许多诊断流程中占据主导地位，而铁基和锰基对比剂则是为了满足特定的安全性和成像目标而设计的。製剂特性，包括化学性质和分子结构（例如，钆配合物的离子型与非离子型，以及锁状与大环结构） ，都会影响其临床性能和安全性。

临床效用涵盖腹部、心血管系统、中枢神经系统和肌肉骨骼系统的成像，对弛豫率、生物分布和清除率的要求各不相同。因此，相关人员必须权衡诊断获益与不断更新的安全证据和监管指南。近年来，人们对钆组织滞留以及易感患者发生肾源性系统性纤维化的风险日益关注，促使人们不断创新并重新评估低剂量製剂方案。因此，现代造影剂的应用不仅要关注其药理学和物理化学特性，还要关注新兴的临床最佳实践、风险缓解策略以及影响产品供应和标籤的法规环境。

这些方向为策略分析奠定了基础。製造商、临床医生和采购负责人将受益于对分子设计、给药途径和最终用途如何共同决定临床应用、安全监测和商业性可行性的清晰理解。随着影像生态系统的演变，这种基本观点使相关人员能够预测整个产业和医疗保健服务体系中产品偏好、投资重点和合作管道的变化。

安全审查、影像技术进步和监管结构调整如何推动MRI造影剂创新和应用领域的策略转变

磁振造影造影剂领域正经历着变革性的转变，其驱动力来自多方面因素：日益严格的安全审查、影像处理通讯协定的进步以及监管和采购环境的重组。安全性问题，尤其是钆滞留相关的问题，促使人们对大环螯合物产生了浓厚的兴趣。与锁状螯合物相比，大环螯合物具有更高的动力学稳定性，并在许多临床领域中逐渐成为首选方案。同时，创新范围已从钆扩展到铁基和锰基对比剂，旨在平衡诊断性能与差异化的安全性和药物动力学特性。

同时，磁振造影硬体和序列设计的改进正在改变对造影剂的需求。高场强扫描仪、定量成像生物标记和人工智慧驱动的后处理有望提高灵敏度并减少对高剂量造影的依赖。这些技术进步促使生产者和临床团队重新评估给药策略，并开发针对特定影像模式优化的造影剂。监管机构也做出了回应，发布了更详细的附加檔、风险沟通和上市后监测指南，鼓励生产商投资长期安全性测试并加强药物安全检测系统。

从商业性角度来看，这种转变正在推动整个价值链的策略重组。开发人员正优先考虑产品组合的合理化，以突出更安全、循证性更强的产品；他们正积极建立跨行业伙伴关係，以加速开发非钆基造影剂；并加强与放射学网络的合作，以支持循证医学证据的生成和应用。因此，该产业正从传统的商品主导模式转向差异化、实证主导的生态系统，在这个系统中，安全性、临床结果和营运整合决定着长期的竞争优势。

2025年，累积驱动的供应链重组和策略性製造决策将再形成整个MRI造影生态系统的采购、供应和营运韧性。

2025年累积关税的实施，导致MRI造影剂生产商、经销商和医疗服务提供者的供应链经济和策略规划发生了重大调整。为此，各公司不得不重新审视其原料药、螯合剂和成品药的筹资策略，尤其关注原料供应商和委託製造生产商的地理分布。这种调整促使企业更加重视供应的安全性和韧性，从而转向多元化的供应商网路和紧急库存策略，以应对进口成本波动和运输中断的影响。

此外，关税环境也影响外商投资和生产能力在地化的决策。一些公司正在评估在境内或近岸生产的优势，以减轻进口关税的影响并缩短医院采购前置作业时间。建立国内生产需要遵守区域监管框架并通过生产流程检验，而这些因素与监管时间表和品质要求相互影响。从采购角度来看，医院和影像中心正在重新谈判合约并寻求定价机制，以降低关税带来的成本风险，而经销商在调整其商业模式，以反映更高的到岸成本并保护其利润结构。

此外，关税背景促使人们更加关注能够降低每位患者消费量量的製剂和给药策略，包括优化给药通讯协定和支持以较低剂量提供同等诊断价值的替代药物。产业相关人员正加强与贸易和卫生当局的对话，以明确关税分类，在合理情况下为重要的临床药物争取豁免，并倡导可预测的贸易惯例，从而保障患者照护的连续性和持续创新。

明确产品化学性质、临床应用、最终用途、分销管道和给药途径如何相互交织，从而确定各细分市场的策略重点。

对细分市场的细緻分析阐明了产品特性、临床应用案例和分销管道如何相互作用，从而确定策略重点和商业化策略。根据产品类型，产品组合通常分为离子型和非离子型製剂。离子型产品主要包括钆基製剂，此类别进一步细分为锁状製剂和大环製剂，因为分子结构会显着影响体内稳定性和安全性。非离子型产品涵盖更广泛的化学成分，包括钆基、铁基和锰基製剂，非离子型钆製剂也根据其分子结构（如适用）按线性或大环结构进行分类。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 提高无钆奈米颗粒的临床应用速率，以提升其安全性
  • 将人工智慧驱动的影像优化演算法整合到磁振造影对比通讯协定中
  • 增加对用于儿科磁振造影的可生物降解大环製剂的探索
  • 线性钆螯合物在新的安全资料公布后，正受到更严格的监管审查。
  • 开发结合MRI造影剂和标靶药物传递的多功能诊疗剂
  • 利用高弛豫性氧化铁奈米颗粒改善老年患者的血管成像
  • 生技Start-Ups与影像中心建立策略伙伴关係，加速新型MRI药物的核准。
  • 病人安全倡议和报销政策变化推动了低剂量造影通讯协定需求的激增
  • 增加对器官特异性造影剂的投资，以优化区分肝臟和肾臟病变。
  • 双模PET-MRI对比探针的出现可提高肿瘤诊断工作流程中的诊断准确性

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依产品类型分類的MRI造影剂市场

  • 离子
    • 钆基药物
      • 线性药物
      • 大环化合物
  • 非离子型
    • 钆基药物
      • 线性药物
      • 大环化合物
    • 铁基药物
    • 锰基药物

9. 依药物类别造影的MRI 造影剂市场

  • 钆基药物
    • 线性药物
    • 大环化合物
  • 铁基药物
  • 锰基药物

第十章：按应用分類的MRI造影剂市场

  • 腹部影像检查
    • 胃肠道影像检查
    • 肝臟影像检查
  • 心血管影像
    • 心臟影像
    • 血管影像
  • 中枢神经系统影像检查
  • 肌肉骨骼影像

第十一章：依最终用途分類的MRI造影剂市场

  • 门诊手术中心
  • 诊断影像中心
  • 医院
    • 社区医院
    • 三级医疗机构
  • 研究所

第十二章 MRI造影剂市场依通路划分

  • 直销
  • 医院药房
  • 网路药房
  • 零售药房

第十三章：依给药途径分類的MRI造影剂市场

  • 关节内给药
  • 静脉注射
  • 口服

第十四章：按地区分類的MRI造影剂市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：按组别分類的MRI造影剂市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国MRI造影剂市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • GE HealthCare Technologies Inc.
    • Bracco Imaging SpA
    • Bayer AG
    • Guerbet SA
    • Lantheus Medical Imaging, Inc.
    • Mallinckrodt plc
    • Fujifilm Holdings Corporation
    • Daiichi Sankyo Company, Limited
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Sichuan Kelun Pharmaceutical Co., Ltd.
Product Code: MRR-F927BA46208C

The MRI Contrast Media Agents Market is projected to grow by USD 4.89 billion at a CAGR of 7.83% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.67 billion
Estimated Year [2025] USD 2.88 billion
Forecast Year [2032] USD 4.89 billion
CAGR (%) 7.83%

An authoritative orientation to MRI contrast media agents that frames chemical diversity, clinical utility, and safety imperatives shaping product development and clinical adoption

Magnetic resonance imaging contrast media agents are integral to modern diagnostic imaging, enhancing tissue contrast and enabling confident interpretation across a broad range of clinical indications. The landscape is chemically diverse, encompassing gadolinium-based agents historically dominant in many diagnostic workflows, alongside iron- and manganese-based alternatives engineered to address specific safety and imaging objectives. Beyond chemistry, formulation attributes such as ionic versus non-ionic character and molecular architecture-specifically linear versus macrocyclic chelation for gadolinium complexes-inform both clinical performance and safety profiles.

Clinical utility spans abdominal, cardiovascular, central nervous system, and musculoskeletal imaging, and these applications drive nuanced requirements for relaxivity, biodistribution, and clearance. Consequently, stakeholders must weigh diagnostic benefits against evolving safety evidence and regulatory guidance. Over recent years, concerns regarding gadolinium retention in tissues and the risk, albeit low, of nephrogenic systemic fibrosis in susceptible patients have catalyzed both innovation and reappraisal of prescribing patterns. Therefore, a contemporary introduction to contrast media must foreground not only pharmacological and physicochemical attributes, but also emerging clinical best practices, risk mitigation measures, and the regulatory environment shaping product availability and labeling.

This orientation sets the stage for strategic analysis: manufacturers, clinicians, and procurement leaders benefit from a clear understanding of how molecular design, administration route, and end-use setting converge to determine clinical adoption, safety monitoring, and commercial viability. As the diagnostic imaging ecosystem evolves, this foundational perspective enables stakeholders to anticipate shifts in product preference, investment priorities, and collaborative pathways across industry and healthcare delivery systems.

How safety scrutiny, imaging technology advances, and regulatory realignment are catalyzing a strategic transformation across MRI contrast agent innovation and adoption

The landscape for MRI contrast agents is undergoing transformative shifts driven by converging forces: heightened safety scrutiny, technological advances in imaging protocols, and a reconfigured regulatory and procurement environment. Safety concerns, particularly those related to gadolinium retention, have accelerated interest in macrocyclic chelates, which offer greater kinetic stability than linear counterparts and are increasingly positioned as preferred options in many clinical pathways. Meanwhile, innovation is expanding beyond gadolinium into iron- and manganese-based agents that aim to balance diagnostic performance with differentiated safety and pharmacokinetic properties.

Concurrently, improvements in MRI hardware and sequence design are altering contrast requirements; higher-field scanners, quantitative imaging biomarkers, and AI-enhanced post-processing can increase sensitivity and may reduce the reliance on high-dose contrast administrations. These technological advances encourage manufacturers and clinical teams to re-evaluate dosing strategies and to develop agents optimized for specific imaging paradigms. Regulatory agencies are responding with more granular guidance on labeling, risk communication, and post-market surveillance, prompting manufacturers to invest in longitudinal safety studies and to strengthen pharmacovigilance infrastructures.

From a commercial perspective, these shifts are prompting strategic realignments across the value chain. Organizations are prioritizing portfolio rationalization to emphasize safer, higher-evidence products, forging cross-sector partnerships to accelerate development of non-gadolinium agents, and enhancing engagement with radiology networks to support evidence generation and adoption. As a result, the sector is transitioning from a legacy, commodity-driven model toward a differentiated, evidence-led ecosystem in which safety, clinical outcomes, and operational integration determine long-term competitive advantage.

Cumulative tariff-driven supply chain recalibrations and strategic manufacturing decisions reshaping sourcing, procurement, and operational resilience across the MRI contrast ecosystem in 2025

The introduction of cumulative tariffs in 2025 has produced a material recalibration of supply chain economics and strategic planning across manufacturers, distributors, and healthcare providers dealing with MRI contrast agents. In response, organizations have had to re-examine sourcing strategies for APIs, chelating agents, and finished formulations, with particular attention to the geographic footprint of raw material suppliers and contract manufacturers. This recalibration has increased the emphasis on supply security and resilience, prompting a shift toward diversified supplier networks and contingency inventory strategies to buffer against import cost volatility and transport disruptions.

Furthermore, the tariff environment has influenced decisions about inward investment and the localization of manufacturing capacity. Some companies are evaluating the benefits of onshore or nearshore production to reduce exposure to import duties and to shorten lead times for hospital procurement cycles. These considerations interact with regulatory timelines and quality requirements, as establishing domestic manufacturing necessitates compliance with regional regulatory frameworks and validation of manufacturing processes. From a procurement perspective, hospitals and imaging centers are renegotiating contracts and seeking pricing mechanisms that mitigate tariff-driven cost exposure, while distributors are adjusting commercial models to reflect increased landed costs and to protect margin structures.

In addition, the tariff context has amplified interest in formulations and administration strategies that reduce per-patient product consumption, including optimizing dosage protocols and supporting alternatives that offer comparable diagnostic value at lower administered mass. Finally, this period has underscored the importance of policy engagement: industry players are intensifying dialogues with trade and health authorities to clarify tariff classifications, pursue exemptions where justified for critical clinical supplies, and advocate for predictable trade policies that support uninterrupted patient care and continued innovation.

Segment-based clarity revealing how product chemistry, clinical applications, end-use settings, distribution channels, and administration routes converge to drive strategic priorities

A granular view of segmentation clarifies how product features, clinical use cases, and distribution pathways interact to define strategic priorities and commercialization tactics. Based on product type, portfolios are commonly divided into ionic and non-ionic formulations. Ionic products predominantly include gadolinium-based agents, and within that category a further distinction is drawn between linear agents and macrocyclic agents because molecular architecture significantly influences in-vivo stability and safety perceptions. Non-ionic product lines encompass a broader chemistry set that includes gadolinium-based agents, iron-based agents, and manganese-based agents, with gadolinium within the non-ionic subset also categorized by linear and macrocyclic structure when applicable.

Based on agent class, the field is organized into gadolinium-based, iron-based, and manganese-based agents, where gadolinium options are again differentiated into linear and macrocyclic forms to reflect differences in chelation stability. Based on application, contrast agents are applied across abdominal imaging, cardiovascular imaging, central nervous system imaging, and musculoskeletal imaging; abdominal imaging itself is subdivided into gastrointestinal and liver imaging while cardiovascular imaging can be decomposed into cardiac and vascular imaging to align with distinct diagnostic protocols and dosing considerations.

Based on end use, the agents are deployed in settings ranging from ambulatory surgical centers and diagnostic imaging centers to hospitals and research institutes, with hospitals further classified into community hospitals and tertiary care centers to reflect variation in case complexity and purchasing behavior. Based on distribution channel, the market engages direct sales to institutional customers as well as hospital pharmacies, online pharmacies, and retail pharmacy channels that serve outpatient demand. Finally, based on administration route, agents are employed through intraarticular, intravenous, and oral administration pathways, each of which presents different formulation, delivery device, and clinical workflow requirements that manufacturers must address in product design and commercialization planning.

Region-specific regulatory, clinical, and supply considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption patterns and strategic positioning

Regional dynamics are a central determinant of product strategy, regulatory planning, and commercial execution, and they vary across major markets such as the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical networks and purchasing aggregates often emphasize evidence-led adoption and large-scale procurement agreements, which influence manufacturers to prioritize robust safety dossiers and streamlined logistics to support national and regional hospital systems. The United States regulatory environment and reimbursement structures in the region shape pricing and market entry strategies, while North American academic centers frequently lead clinical research that informs global guidelines.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and clinical practices where pan-regional harmonization efforts coexist with country-level variation. European regulatory authorities have been active on safety communication and post-market surveillance, prompting manufacturers to tailor pharmacovigilance and labeling across jurisdictions. In the Middle East and Africa, infrastructure constraints and regional procurement models create different adoption timelines, and stakeholders may prioritize cost-effective formulations and logistical simplicity when implementing contrast-enhanced imaging programs.

Asia-Pacific is characterized by rapid capacity expansion, diverse regulatory maturity, and strong manufacturing ecosystems for both API and finished products. Several markets in the region combine large patient volumes with growing diagnostic capabilities, encouraging local manufacturers and global companies to form partnerships and to invest in regional clinical evidence generation. Across these regions, strategic differentiation rests on aligning product attributes with local clinical practice, regulatory expectations, and distribution realities to optimize adoption and sustain supply continuity.

How incumbent pharmaceutical and specialty developers are pursuing evidence, supply integration, and partnerships to sustain competitive advantage in MRI contrast media

Competitive dynamics in the MRI contrast agent space are shaped by incumbent pharmaceutical and medical imaging companies, alongside nimble specialty developers advancing novel chemistries and targeted formulations. Established players focus on portfolio optimization, safety evidence generation, and scale efficiencies in manufacturing and distribution. These companies often invest in reformulations, new labeling claims, and targeted clinical studies to defend and reposition legacy products in a market increasingly attentive to retention risk and chelate stability. At the same time, smaller biotechnology firms and specialty pharmaceutical companies are advancing iron- and manganese-based agents that offer differentiated safety or functional imaging properties, driving partnerships and licensing activity as a pragmatic route to commercialization.

Strategic behaviors include vertical integration of supply chains to secure critical raw materials, collaboration with imaging device manufacturers to demonstrate product-device synergies, and selective geographic expansion guided by regulatory and clinical research priorities. In addition, there is an increasing focus on real-world evidence generation and health economics research to articulate value propositions for hospital procurement committees and payers. Distribution partners and specialty pharmacies are adapting commercial models to support complex logistics for contrast media that require cold chain management, controlled inventory oversight, and alignment with hospital formularies.

Taken together, these dynamics suggest that competitive advantage will accrue to organizations that can marry high-quality safety and efficacy evidence with reliable, flexible supply capabilities, and that can translate clinical differentiation into operational and economic benefits for healthcare providers.

Practical strategic actions for industry leaders to secure supply, strengthen safety evidence, and accelerate clinical adoption while mitigating tariff and regulatory risks

Leaders seeking to preserve and expand their position in the MRI contrast media domain should adopt a set of actionable strategies that emphasize safety, supply-chain resilience, and evidence-driven commercialization. First, prioritize investment in molecular designs and formulations with demonstrable stability and safety profiles, while advancing the clinical data necessary to support differentiated labeling and clinician confidence. Second, diversify procurement and manufacturing footprints to reduce exposure to tariff fluctuations and logistic disruptions, including evaluating nearshoring or qualified dual-sourcing for critical inputs.

Third, accelerate clinical and real-world evidence programs that directly address clinician concerns about retention and adverse events, and align these programs with regulatory reporting requirements to build trust with governing agencies. Fourth, develop commercial models that integrate with hospital formularies and imaging workflows, offering education, protocol optimization, and economic analyses to support adoption. Fifth, pursue strategic collaborations with imaging device manufacturers, academic research centers, and contract research organizations to expedite validation of agent-device synergies and to expand indications where appropriate. Finally, refine distribution strategies by blending direct sales to large institutional customers with pharmacy channel partnerships to reach outpatient markets, while ensuring rigorous cold chain and inventory controls.

By implementing these interlocking initiatives, organizations can reduce operational risk, strengthen clinical credibility, and create differentiated value propositions that resonate with radiologists, procurement leaders, and institutional payers.

A rigorous mixed-methods research approach integrating clinician interviews, regulatory review, and evidence triangulation to yield actionable strategic insight

The research underpinning this analysis combined primary qualitative engagement with domain experts, comprehensive review of regulatory and clinical literature, and triangulation against public clinical trial registries and patent filings. Primary inputs included structured interviews with practicing radiologists, pharmacovigilance specialists, hospital procurement leaders, and R&D executives to capture firsthand perspectives on clinical needs, adoption barriers, and supply chain priorities. Secondary sources encompassed regulatory communications, peer-reviewed safety and efficacy studies, and technical documentation relating to chelation chemistry and formulation approaches.

Methodologically, findings were synthesized through a layered approach: clinical insights were cross-referenced with regulatory trends to assess likely labeling and surveillance implications; manufacturing and distribution considerations were modeled qualitatively to identify resilience levers under tariff pressures; and competitive strategies were validated through analysis of corporate disclosures and partnership announcements. Emphasis was placed on extracting actionable implications rather than quantitative market sizing, and all conclusions were tested for plausibility against multiple independent sources to ensure robustness and relevance for decision-makers.

Synthesis of clinical, operational, and policy imperatives that define strategic pathways for resilient and patient-centric MRI contrast media portfolios

In conclusion, the MRI contrast media landscape is at an inflection point in which safety imperatives, technological advances, and external policy dynamics collectively shape near- and medium-term strategy. Stakeholders must balance the established diagnostic utility of gadolinium-based agents with the need to respond to retention concerns by prioritizing macrocyclic chemistries and advancing non-gadolinium alternatives where clinically appropriate. At the same time, the operational and commercial impacts of trade policy shifts necessitate a renewed focus on supply chain diversification and manufacturing flexibility to maintain uninterrupted patient care.

Looking ahead, organizations that invest in high-quality clinical evidence, engage proactively with regulators, and construct resilient distribution and production architectures will be better positioned to navigate evolving clinical preferences and procurement pressures. Collaboration across the value chain-including partnerships between specialty developers, established suppliers, imaging device firms, and healthcare providers-will accelerate the development and adoption of safer, more effective contrast solutions. Ultimately, strategic success will depend on integrating scientific rigor with operational adaptability to meet the diagnostic needs of clinicians while protecting patients and sustaining long-term commercial viability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing clinical adoption of gadolinium-free nanoparticles for enhanced safety profiles
  • 5.2. Integration of AI-driven image optimization algorithms in MR contrast protocols
  • 5.3. Rising research into biodegradable macrocyclic agents for pediatric MRI applications
  • 5.4. Regulatory scrutiny intensifying around linear gadolinium chelates following new safety data
  • 5.5. Development of multifunctional theranostic agents combining MRI contrast with targeted drug delivery
  • 5.6. Expansion of high-relaxivity iron oxide nanoparticles for improved vascular imaging in elderly patients
  • 5.7. Strategic collaborations between biotech startups and imaging centers to accelerate novel MRI agent approvals
  • 5.8. Surge in demand for low-dose contrast protocols driven by patient safety advocacy and reimbursement changes
  • 5.9. Growing investment in organ-specific contrast agents optimized for hepatic and renal lesion differentiation
  • 5.10. Emergence of dual-modal PET-MRI contrast probes enhancing diagnostic accuracy in oncology workflows

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. MRI Contrast Media Agents Market, by Product Type

  • 8.1. Ionic
    • 8.1.1. Gadolinium Based Agents
      • 8.1.1.1. Linear Agents
      • 8.1.1.2. Macrocyclic Agents
  • 8.2. Non Ionic
    • 8.2.1. Gadolinium Based Agents
      • 8.2.1.1. Linear Agents
      • 8.2.1.2. Macrocyclic Agents
    • 8.2.2. Iron Based Agents
    • 8.2.3. Manganese Based Agents

9. MRI Contrast Media Agents Market, by Agent Class

  • 9.1. Gadolinium Based Agents
    • 9.1.1. Linear Agents
    • 9.1.2. Macrocyclic Agents
  • 9.2. Iron Based Agents
  • 9.3. Manganese Based Agents

10. MRI Contrast Media Agents Market, by Application

  • 10.1. Abdominal Imaging
    • 10.1.1. Gastrointestinal Imaging
    • 10.1.2. Liver Imaging
  • 10.2. Cardiovascular Imaging
    • 10.2.1. Cardiac Imaging
    • 10.2.2. Vascular Imaging
  • 10.3. Central Nervous System Imaging
  • 10.4. Musculoskeletal Imaging

11. MRI Contrast Media Agents Market, by End Use

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospitals
    • 11.3.1. Community Hospitals
    • 11.3.2. Tertiary Care Hospitals
  • 11.4. Research Institutes

12. MRI Contrast Media Agents Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. MRI Contrast Media Agents Market, by Administration Route

  • 13.1. Intraarticular Administration
  • 13.2. Intravenous Administration
  • 13.3. Oral Administration

14. MRI Contrast Media Agents Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. MRI Contrast Media Agents Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. MRI Contrast Media Agents Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. GE HealthCare Technologies Inc.
    • 17.3.2. Bracco Imaging S.p.A.
    • 17.3.3. Bayer AG
    • 17.3.4. Guerbet SA
    • 17.3.5. Lantheus Medical Imaging, Inc.
    • 17.3.6. Mallinckrodt plc
    • 17.3.7. Fujifilm Holdings Corporation
    • 17.3.8. Daiichi Sankyo Company, Limited
    • 17.3.9. Jiangsu Hengrui Medicine Co., Ltd.
    • 17.3.10. Sichuan Kelun Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. MRI CONTRAST MEDIA AGENTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. MRI CONTRAST MEDIA AGENTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MRI CONTRAST MEDIA AGENTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LINEAR AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MACROCYCLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IRON BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MANGANESE BASED AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY LIVER IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIAC IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY VASCULAR IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY MUSCULOSKELETAL IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAARTICULAR ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ABDOMINAL IMAGING, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY CARDIOVASCULAR IMAGING, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY END USE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY IONIC, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY NON IONIC, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA MRI CONTRAST MEDIA AGENTS MARKET SIZE, BY AGENT CLASS, 2025-2032 (USD MILLION